Literature DB >> 27503926

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.

Warren Fiskus1, Veena Coothankandaswamy2, Jianguang Chen3, Hongwei Ma4, Kyungsoo Ha5, Dyana T Saenz1, Stephanie S Krieger1, Christopher P Mill1, Baohua Sun1, Peng Huang6, Jeffrey S Mumm7, Ari M Melnick8, Kapil N Bhalla9.   

Abstract

SIRT2 is a protein deacetylase with tumor suppressor activity in breast and liver tumors where it is mutated; however, the critical substrates mediating its antitumor activity are not fully defined. Here we demonstrate that SIRT2 binds, deacetylates, and inhibits the peroxidase activity of the antioxidant protein peroxiredoxin (Prdx-1) in breast cancer cells. Ectopic overexpression of SIRT2, but not its catalytically dead mutant, increased intracellular levels of reactive oxygen species (ROS) induced by hydrogen peroxide, which led to increased levels of an overoxidized and multimeric form of Prdx-1 with activity as a molecular chaperone. Elevated levels of SIRT2 sensitized breast cancer cells to intracellular DNA damage and cell death induced by oxidative stress, as associated with increased levels of nuclear FOXO3A and the proapoptotic BIM protein. In addition, elevated levels of SIRT2 sensitized breast cancer cells to arsenic trioxide, an approved therapeutic agent, along with other intracellular ROS-inducing agents. Conversely, antisense RNA-mediated attenuation of SIRT2 reversed ROS-induced toxicity as demonstrated in a zebrafish embryo model system. Collectively, our findings suggest that the tumor suppressor activity of SIRT2 requires its ability to restrict the antioxidant activity of Prdx-1, thereby sensitizing breast cancer cells to ROS-induced DNA damage and cell cytotoxicity. Cancer Res; 76(18); 5467-78. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27503926      PMCID: PMC5345574          DOI: 10.1158/0008-5472.CAN-16-0126

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.

Authors:  Hyun-Seok Kim; Athanassios Vassilopoulos; Rui-Hong Wang; Tyler Lahusen; Zhen Xiao; Xiaoling Xu; Cuiling Li; Timothy D Veenstra; Bing Li; Hongtao Yu; Junfang Ji; Xin Wei Wang; Seong-Hoon Park; Yong I Cha; David Gius; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1.

Authors:  Rachel A Egler; Elaine Fernandes; Kristi Rothermund; Susan Sereika; Nadja de Souza-Pinto; Pawel Jaruga; Miral Dizdaroglu; Edward V Prochownik
Journal:  Oncogene       Date:  2005-12-01       Impact factor: 9.867

3.  Oxidative stress-dependent structural and functional switching of a human 2-Cys peroxiredoxin isotype II that enhances HeLa cell resistance to H2O2-induced cell death.

Authors:  Jeong Chan Moon; Young-Sool Hah; Woe Yeon Kim; Bae Gyo Jung; Ho Hee Jang; Jung Ro Lee; Sun Young Kim; Young Mee Lee; Min Gyu Jeon; Choong Won Kim; Moo Je Cho; Sang Yeol Lee
Journal:  J Biol Chem       Date:  2005-06-07       Impact factor: 5.157

4.  Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.

Authors:  Yun-Jeong Kim; Ji-Yeon Ahn; Ping Liang; Clement Ip; Yuesheng Zhang; Young-Mee Park
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

5.  Activity assay of mammalian 2-cys peroxiredoxins using yeast thioredoxin reductase system.

Authors:  Ju-A Kim; Sunjoo Park; Kangwha Kim; Sue Goo Rhee; Sang Won Kang
Journal:  Anal Biochem       Date:  2005-03-15       Impact factor: 3.365

6.  Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.

Authors:  Joo-Heon Kim; Paul N Bogner; Sun-Hee Baek; Nithya Ramnath; Ping Liang; Hak-Ryul Kim; Chris Andrews; Young-Mee Park
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

Review 7.  Structure, mechanism and regulation of peroxiredoxins.

Authors:  Zachary A Wood; Ewald Schröder; J Robin Harris; Leslie B Poole
Journal:  Trends Biochem Sci       Date:  2003-01       Impact factor: 13.807

8.  Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.

Authors:  Changyi Quan; Eun-Jong Cha; Hyung-Lae Lee; Kwang Hee Han; Keon Myung Lee; Wun-Jae Kim
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

Review 9.  Are peroxiredoxins tumor suppressors?

Authors:  Carola Anke Neumann; Quan Fang
Journal:  Curr Opin Pharmacol       Date:  2007-07-05       Impact factor: 5.547

10.  SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction.

Authors:  Fei Wang; Margaret Nguyen; F Xiao-Feng Qin; Qiang Tong
Journal:  Aging Cell       Date:  2007-05-23       Impact factor: 9.304

View more
  23 in total

Review 1.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  The Multifaceted Impact of Peroxiredoxins on Aging and Disease.

Authors:  Svetlana N Radyuk; William C Orr
Journal:  Antioxid Redox Signal       Date:  2018-01-17       Impact factor: 8.401

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

5.  Chemoproteomics Reveals Chemical Diversity and Dynamics of 4-Oxo-2-nonenal Modifications in Cells.

Authors:  Rui Sun; Ling Fu; Keke Liu; Caiping Tian; Yong Yang; Keri A Tallman; Ned A Porter; Daniel C Liebler; Jing Yang
Journal:  Mol Cell Proteomics       Date:  2017-08-16       Impact factor: 5.911

6.  Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients.

Authors:  Pengfei Shi; Min Zhou; Yonggang Yang
Journal:  Ir J Med Sci       Date:  2019-08-15       Impact factor: 1.568

7.  SIRT2 and Lysine Fatty Acylation Regulate the Activity of RalB and Cell Migration.

Authors:  Nicole A Spiegelman; Xiaoyu Zhang; Hui Jing; Ji Cao; Ilana B Kotliar; Pornpun Aramsangtienchai; Miao Wang; Zhen Tong; Kelly M Rosch; Hening Lin
Journal:  ACS Chem Biol       Date:  2019-09-03       Impact factor: 5.100

Review 8.  The Role of Sirtuins in Antioxidant and Redox Signaling.

Authors:  Chandra K Singh; Gagan Chhabra; Mary Ann Ndiaye; Liz Mariely Garcia-Peterson; Nicholas J Mack; Nihal Ahmad
Journal:  Antioxid Redox Signal       Date:  2017-10-20       Impact factor: 8.401

9.  SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases.

Authors:  Bo Wang; Yingjiang Ye; Xin Yang; Boya Liu; Zhe Wang; Shuaiyi Chen; Kewei Jiang; Wei Zhang; Hongpeng Jiang; Harri Mustonen; Pauli Puolakkainen; Shan Wang; Jianyuan Luo; Zhanlong Shen
Journal:  EMBO Rep       Date:  2020-03-05       Impact factor: 8.807

10.  Nrf2 Down-Regulation by Camptothecin Favors Inhibiting Invasion, Metastasis and Angiogenesis in Hepatocellular Carcinoma.

Authors:  Qian Liu; Shanshan Zhao; Fanguang Meng; Hankang Wang; Liwei Sun; Guijie Li; Feng Gao; Feng Chen
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.